Cite
High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network.
MLA
Marchesi, F., et al. “High Incidence of Post-Transplant Cytomegalovirus Reactivations in Myeloma Patients Undergoing Autologous Stem Cell Transplantation after Treatment with Bortezomib-Based Regimens: A Survey from the Rome Transplant Network.” Transplant Infectious Disease : An Official Journal of the Transplantation Society, vol. 16, no. 1, Feb. 2014, pp. 158–64. EBSCOhost, https://doi.org/10.1111/tid.12162.
APA
Marchesi, F., Mengarelli, A., Giannotti, F., Tendas, A., Anaclerico, B., Porrini, R., Picardi, A., Cerchiara, E., Dentamaro, T., Chierichini, A., Romeo, A., Cudillo, L., Montefusco, E., Tirindelli, M. C., De Fabritiis, P., Annino, L., Petti, M. C., Monarca, B., Arcese, W., & Avvisati, G. (2014). High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network. Transplant Infectious Disease : An Official Journal of the Transplantation Society, 16(1), 158–164. https://doi.org/10.1111/tid.12162
Chicago
Marchesi, F, A Mengarelli, F Giannotti, A Tendas, B Anaclerico, R Porrini, A Picardi, et al. 2014. “High Incidence of Post-Transplant Cytomegalovirus Reactivations in Myeloma Patients Undergoing Autologous Stem Cell Transplantation after Treatment with Bortezomib-Based Regimens: A Survey from the Rome Transplant Network.” Transplant Infectious Disease : An Official Journal of the Transplantation Society 16 (1): 158–64. doi:10.1111/tid.12162.